| Followers | 65 |
| Posts | 10174 |
| Boards Moderated | 0 |
| Alias Born | 03/29/2015 |
Friday, November 10, 2023 11:50:08 PM
Welcome to NWBO investing.
From an investor standpoint now seems to be a good time and a good price to buy and you are likely to do better than investors who have waited far longer and none of us begrudge you that.
We are likely to have a mini-catalyst this month when NWBO announces submission to MHRA and this will likely help build excitement because the clock will be started on an up or down approval decision (which I believe will be up) as NWBO has home town advantage since the company manufactures in the UK and there is no effective treatment for GBM.
A lot of investors look for the chance to jump into stocks that will have a binary catalyst any day and that should attract new investors which will help raise the SP over time up until the catalyst when we will have the potential for the kind of increase we have waited a decade for.
From a patient family member perspective the outlook is not nearly as positive. DCVax-L and Direct are great products and you should investigate then first and see if they are available via compassionate use or a trial for those close to you. Unfortunately at the rate things have been going, neither of these products is likely to be available with insurance reimbursement within a time frame for someone already diagnosed with cancer like your family member. Thus while NWBO is likely a rewarding investment you would do well to continue due diligence on the overall treatment landscape since time is probably if the essence for your relative.
From an investor standpoint now seems to be a good time and a good price to buy and you are likely to do better than investors who have waited far longer and none of us begrudge you that.
We are likely to have a mini-catalyst this month when NWBO announces submission to MHRA and this will likely help build excitement because the clock will be started on an up or down approval decision (which I believe will be up) as NWBO has home town advantage since the company manufactures in the UK and there is no effective treatment for GBM.
A lot of investors look for the chance to jump into stocks that will have a binary catalyst any day and that should attract new investors which will help raise the SP over time up until the catalyst when we will have the potential for the kind of increase we have waited a decade for.
From a patient family member perspective the outlook is not nearly as positive. DCVax-L and Direct are great products and you should investigate then first and see if they are available via compassionate use or a trial for those close to you. Unfortunately at the rate things have been going, neither of these products is likely to be available with insurance reimbursement within a time frame for someone already diagnosed with cancer like your family member. Thus while NWBO is likely a rewarding investment you would do well to continue due diligence on the overall treatment landscape since time is probably if the essence for your relative.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
